|
CNBC'S MOST SHARED
- Unemployed? Bored? Make Money Playing Beer Pong
- The Highest Grossing (Inflation Adjusted) Movies of All Time
- Merrill's McCann Seen as UBS Wealth Frontrunner
- Geek Squad V. Gizmodo
- Social Networking's 'Naked' Truth
- Warren Buffett's Top Three Investment Rules for the Average American
- Why You Should Watch Fund Flows
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Dykstra Discusses Bankruptcy
- Cheney Told CIA to Withhold Information: Report
- Why the Credit Pendulum Is Stuck at 'Stupid'
- Stimulus Will Kick in Later this Year: President Obama
- Lender CIT Group Hires Premier Bankruptcy Adviser
- Government Selling Bank Stakes for Too Cheap: Panel
- Buffett's Top 3 Investment Rules for Average Americans
- Market Insider: Earnings Loom in the Week Ahead
- Bulls Get Summertime Blues, But It's Hot Fun for Bears
- As Banks Fail, Strong Institutions Become More Visible
- Eric Schmidt on Government Scrutiny and Economic Recovery
- Market 360: The Week's Best & Worst
- Geek Squad V. Gizmodo
- Brandt: Google Chrome OS in the Post-PC Age
- Other People Are Weirder Than We Are
- Bank Failures: Is The Nightmare Over? (Video)
- California Here I Go? No.
- Roginsky: No More Mr. Nice Guy
- Commercial Conundrum
A trial of Celgene's [CELG
Loading...
()
] cancer drug Revlimid was temporarily suspended as of April 4, according to the Southwest Oncology Group, or SWOG, which was running the late-stage trial.
The statement, made on the group's Web site, did not give details.
However, Matthew Osborne, an analyst at Lazard Capital Markets, said he believes the suspension is designed to alter the protocol to allow patients to switch to a different treatment regimen, which was recently shown to improve survival.
Brian Gill, a spokesman for Celgene, confirmed that the trial has been temporarily closed but said the company could shed no light on the reason for the suspension.
"Matt Osborne's assumptions are very interesting and could well have validity but we don't have any definitive information," he said.
The SWOG study is testing Revlimid plus standard dose dexamethasone, a steroid, versus dexamethasone alone as a first-line treatment for multiple myeloma.
The news comes on the heels of a recent finding by the Eastern Cooperative Oncology Group, or ECOG, that patients who took Revlimid plus low-dose dexamethasone had a survival advantage over patients who took Revlimid plus standard dose dexamethasone.
It is not clear whether SWOG plans to stop the trial completely, but Osborne said that with a survival advantage for Revlimid plus low-dose dexamethasone it could be considered unethical to continue patients on standard dose dexamethasone alone.
"What this does is build on the evidence that Revlimid plus low-dose dexamethasone will become the standard of care in frontline multiple myeloma," Osborne said.
Currently, Revlimid is approved by the U.S. Food and Drug Administration in combination with standard-dose dexamethasone for patients with multiple myeloma who have received at least one prior therapy.
Osborne said, however, that as data from the Revlimid plus dexamethasone trials is further disseminated, physicians are likely to increase their use of Revlimid plus low-dose dexamethasone as their first choice therapy, even though it has not formally been approved for such use.
Physicians are allowed to prescribe drugs "off label" but companies are not allowed to market them for unapproved uses.
Revlimid is a successor to Celgene's drug Thalomid, currently the leading treatment for multiple myeloma.








